Edgar Filing: CHIASMA, INC - Form 4

CHIASMA Form 4 July 21, 201 FORN	5 A 4 UNITED STATE		AND EXCH n, D.C. 2054		E CO	OMMISSION	OMB AF OMB Number:	PPROVAL 3235-0287 January 31,		
Check tl if no lor subject to Section Form 4 Form 5 obligation may cor See Instr	so 16. or Filed pursuant to Dns stinue. 20(h	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								
1(b). (Print or Type	Responses)									
1. Name and Address of Reporting Person 2. Issue GADICKE ANSBERT Symbol			nd Ticker or Tra C [CHMA]		5. Relationship of Reporting Person(s) to Issuer					
(Last) (First) (Middle) 3. Date of (Month/E			Pate of Earliest Transaction onth/Day/Year) 21/2015				(Check all applicable) <u>X</u> Director <u>X</u> 10% Owner Officer (give title Other (specify below)			
CAMBRIE	(Street) DGE, MA 02142	4. If Amendment, Filed(Month/Day/Yo	Ionth/Day/Year) ApplX_				ndividual or Joint/Group Filing(Check licable Line) Form filed by One Reporting Person Form filed by More than One Reporting son			
(City)	(State) (Zip)	Table I - Non	-Derivative Sec	urities		ired, Disposed of,	or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	any		tioror Disposed ((Instr. 3, 4 an)	of (D)	red (A) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	07/21/2015	C	10,426 <u>(1)</u>	A	(<u>2</u>)	10,426	Ι	See Footnote		
Common Stock	07/21/2015	С	2,488,171 (4)	А	<u>(2)</u>	2,498,597	Ι	See Footnote		
Common Stock	07/21/2015	С	1,759,381 (6)	А	<u>(2)</u>	4,257,978	Ι	See Footnote		
Common Stock	07/21/2015	С	1,423,566 (8)	А	<u>(2)</u>	5,681,544	Ι	See Footnote		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount o Number o Shares
Series B-1' Preferred Stock	<u>(2)</u>	07/21/2015		С		95,225 <u>(1)</u>	(2)	(2)	Common Stock	10,426
Series C' Preferred Stock	(2)	07/21/2015		C		22,721,988 (4)	(2)	(2)	Common Stock	2,488,1 (4)
Series D' Preferred Stock	(2)	07/21/2015		С		16,066,669 (6)	(2)	<u>(2)</u>	Common Stock	1,759,3 <u>(6)</u>
Series E Preferred Stock	<u>(2)</u>	07/21/2015		С		13,000,000 (8)	(2)	(2)	Common Stock	1,423,5 (8)

Reporting Owners

Reporting Owner Name / Addr	ess	Relationships							
	Director	10% Owner	Officer	Other					
GADICKE ANSBERT C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA 02142	Х	Х							
Signatures									
/s/ Ansbert Gadicke	07/21/2015								
	Date								

<u>**</u>Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares, on a common stock equivalent basis, were converted as follows: 9,773 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 376 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 277 by MPM Asset Management Investors BV4 LLC ("AM
(1) BV4"). MPM BioVentures IV GP LLC ("BV GP LLC") and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

The shares of Series B-1' Preferred Stock, Series C' Preferred Stock, Series D' Preferred Stock and Series E Preferred Stock converted
 (2) into 0.109505 of a share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date.

(3) The shares are held as follows: 9,773 by BV IV QP, 376 by BV IV KG and 277 by AM BV4. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

The shares, on a common stock equivalent basis, were converted as follows: 1,479,910 by BV IV QP, 57,016 by BV IV KG, 42,083 by AM BV4 and 909,162 by MPM Bio IV NVS Strategic Fund, L.P. ("BV IV SF"). BV GP LLC and BV LLC are the direct and indirect

- (4) general partners of BV IV SF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- (5) The shares are held as follows: 1,489,683 by BV IV QP, 57,392 by BV IV KG, 42,360 by AM BV4 and 909,162 by BV IV SF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

The shares, on a common stock equivalent basis, were converted as follows: 1,539,486 by BV IV QP, 59,313 by BV IV KG, 43,776 by(6) AM BV4 and 116,806 by BV IV SF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

(7) The shares are held as follows: 3,029,169 by BV IV QP, 116,705 by BV IV KG, 86,136 by AM BV4 and 1,025,968 by BV IV SF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

The shares, on a common stock equivalent basis, were converted as follows: 939,089 by BV IV QP, 36,179 by BV IV KG, 26,704 by AM
(8) BV4 and 421,594 by BV IV SF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

(9) The shares are held as follows: 3,968,258 by BV IV QP, 152,884 by BV IV KG, 112,840 by AM BV4 and 1,447,562 by BV IV SF. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.